PDCD1 and cancer: Currently there are 3 approved PD-1 inhibitors, namely nivolumab, pembrolizumab and cemiplimab; and 3 approved PD-L1 inhibitors, atezolizumab durvalumab and avelumab for treating multiple types of cancer (11, 12).